Indication
As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

Medicine details

Medicine name:
benralizumab (Fasenra)
SMC ID:
SMC2155
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Submission type
Full
Status
Advice due date:
10 June 2019
SMC meeting date:
07 May 2019
Patient group submission deadline:
01 April 2019